HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloabla...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2016/7802967 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561600688553984 |
|---|---|
| author | Andrea Bacigalupo Simona Sica |
| author_facet | Andrea Bacigalupo Simona Sica |
| author_sort | Andrea Bacigalupo |
| collection | DOAJ |
| description | The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloablative as well as myeloablative conditioning regimens, for bone marrow or peripheral blood grafts, for patients with malignant and nonmalignant disorders. Retrospective comparisons of HAPLO grafts with conventional sibling and unrelated donor grafts have been published and suggest comparable outcome. The current questions to be answered include the use of PT-CY for sibling and unrelated donors transplant, possibly in the context of prospective randomized trial. |
| format | Article |
| id | doaj-art-eb0c63befe2146688dac7ce5e01c637b |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-eb0c63befe2146688dac7ce5e01c637b2025-02-03T01:24:40ZengWileyAdvances in Hematology1687-91041687-91122016-01-01201610.1155/2016/78029677802967HLA Haplotype Mismatch Transplants and Posttransplant CyclophosphamideAndrea Bacigalupo0Simona Sica1Istituto di Ematologia, Universita’ Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, ItalyIstituto di Ematologia, Universita’ Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, ItalyThe use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloablative as well as myeloablative conditioning regimens, for bone marrow or peripheral blood grafts, for patients with malignant and nonmalignant disorders. Retrospective comparisons of HAPLO grafts with conventional sibling and unrelated donor grafts have been published and suggest comparable outcome. The current questions to be answered include the use of PT-CY for sibling and unrelated donors transplant, possibly in the context of prospective randomized trial.http://dx.doi.org/10.1155/2016/7802967 |
| spellingShingle | Andrea Bacigalupo Simona Sica HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide Advances in Hematology |
| title | HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide |
| title_full | HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide |
| title_fullStr | HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide |
| title_full_unstemmed | HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide |
| title_short | HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide |
| title_sort | hla haplotype mismatch transplants and posttransplant cyclophosphamide |
| url | http://dx.doi.org/10.1155/2016/7802967 |
| work_keys_str_mv | AT andreabacigalupo hlahaplotypemismatchtransplantsandposttransplantcyclophosphamide AT simonasica hlahaplotypemismatchtransplantsandposttransplantcyclophosphamide |